BioCardia, Inc. (BCDA) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BioCardia, Inc. (BCDA) Healthcare & Pipeline Overview

BioCardia, Inc. is a clinical-stage biotechnology firm specializing in regenerative medicine, with a focus on innovative cellular therapies for cardiac and respiratory diseases, particularly through its CardiAMP Cell Therapy System and advanced delivery technologies.

What Is the Investment Thesis for BCDA?

BioCardia, Inc. represents a unique opportunity in the biotechnology sector, driven by its innovative CardiAMP Cell Therapy System, which has shown promising clinical trial data for heart failure and chronic myocardial ischemia. The company's focus on regenerative medicine positions it well within a growing market projected to reach $20 billion by 2028. Key value drivers include the ongoing Phase I/II trials for its allogeneic cell therapy program, which could expand its product offerings and market reach. The successful execution of these trials and subsequent regulatory approvals could lead to significant revenue growth. However, investors should be aware of inherent risks associated with clinical-stage companies, including potential regulatory hurdles and the need for further financing to support ongoing research and development. Monitoring upcoming clinical trial results and regulatory milestones will be crucial for assessing the company's future performance.

Based on FMP financials and quantitative analysis

BCDA Key Highlights

Market Cap of $0.01B indicates a small-cap status with potential for growth.

• Beta of 0.50 suggests lower volatility compared to the broader market.
• No dividend yield as the company reinvests earnings into R&D.
• Focus on advanced cellular therapies aligns with increasing demand in regenerative medicine.
• Strong pipeline with CardiAMP Cell Therapy System and allogeneic cell therapy program.

Who Are BCDA's Competitors?

BCDA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are BCDA's Key Strengths?

Innovative product pipeline with the CardiAMP Cell Therapy System.

• Strong focus on regenerative medicine, addressing unmet medical needs.
• Experienced leadership team with expertise in biotechnology.

What Are BCDA's Weaknesses?

Limited financial resources due to the clinical-stage status.

• Small workforce may limit operational capacity and scalability.
• Dependence on successful clinical trial outcomes for growth.

What Could Drive BCDA Stock Higher?

BCDA catalyst: Results from ongoing Phase I/II trials for the allogeneic cell therapy program could provide insights into efficacy and safety.

• Development of the CardiAMP Cell Therapy System continues to progress, with clinical trials expected to yield data in the near term.
• Potential partnerships with healthcare providers could enhance BioCardia's market presence and accelerate product development.

What Are the Key Risks for BCDA?

Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.

• Regulatory approval processes may pose challenges and delays for product launches.
• The need for additional financing could impact operational capabilities and growth initiatives.
• Competition from established biotechnology firms may affect market share and pricing strategies.

What Are the Growth Opportunities for BCDA?

• Growth opportunity 1: The global regenerative medicine market is expected to reach $20 billion by 2028, driven by increasing investments in research and development. BioCardia's focus on innovative therapies for cardiac and respiratory conditions positions it to capture a significant share of this growing market. The ongoing clinical trials for the CardiAMP Cell Therapy System could lead to market entry and revenue generation within the next 2-3 years, depending on regulatory approvals.
• Growth opportunity 2: BioCardia's allogeneic cell therapy program is currently in Phase I/II trials, targeting ischemic systolic heart failure. If successful, this program could provide a new revenue stream and enhance the company's product portfolio. The increasing prevalence of heart failure, projected to affect over 8 million individuals in the U.S. by 2030, presents a substantial market opportunity for BioCardia's therapies.
• Growth opportunity 3: The Helix biotherapeutic delivery system represents a significant innovation in the delivery of cell therapies. By enabling precise administration of treatments directly into the heart muscle, this technology could improve patient outcomes and increase the efficacy of BioCardia's therapies. As the demand for effective delivery systems grows, BioCardia's proprietary technology could become a competitive advantage in the market.
• Growth opportunity 4: Partnerships with healthcare providers and research institutions could enhance BioCardia's clinical trial capabilities and expand its reach in the regenerative medicine space. Collaborations could lead to accelerated development timelines and increased visibility within the industry, fostering growth opportunities.
• Growth opportunity 5: The increasing focus on personalized medicine and tailored therapies aligns with BioCardia's approach of using patient-derived cells for treatment. As healthcare shifts towards more individualized treatment plans, BioCardia's innovative therapies could meet the evolving needs of patients and healthcare providers.

What Threats Does BCDA Face?

• Regulatory hurdles could delay product approvals and market entry.
• Intense competition in the biotechnology sector may impact market share.
• Funding challenges may hinder research and development efforts.

What Are BCDA's Competitive Advantages?

• Proprietary technology for the CardiAMP Cell Therapy System differentiates BioCardia from competitors.
• Innovative delivery systems enhance treatment efficacy and patient outcomes.
• Strong focus on clinical trials and research positions the company as a leader in regenerative medicine.
• Expertise in cellular therapies provides a competitive edge in a rapidly evolving market.

What Does BCDA Do?

Founded with a vision to transform the treatment landscape for cardiac and respiratory ailments, BioCardia, Inc. is a pioneering clinical-stage biotechnology company headquartered in Sunnyvale, California. The company's primary focus is on regenerative medicine, specifically the development of advanced cellular and cell-derived therapies. Central to its pipeline is the CardiAMP Cell Therapy System, which is designed to address significant medical challenges such as heart failure and chronic myocardial ischemia. This innovative system utilizes a patient’s own cells to promote healing and regeneration of damaged heart tissue. In addition to the CardiAMP system, BioCardia is advancing an allogeneic cell therapy program targeting both cardiac and pulmonary conditions. This investigational treatment, derived from culture-expanded mesenchymal cells sourced from bone marrow, is currently undergoing Phase I/II trials for patients suffering from ischemic systolic heart failure. The company is also exploring a specific allogeneic cell therapeutic platform that could further enhance its treatment offerings. Beyond its therapeutic candidates, BioCardia provides innovative delivery solutions, including the Helix biotherapeutic delivery system, which is engineered to precisely administer treatments directly into the heart muscle via an internal penetrating helical needle. The company also offers a line of Morph deflectable guides and sheaths, facilitating enhanced delivery of its therapies. With a dedicated team of 17 employees, BioCardia is positioned to make significant strides in the regenerative medicine space, aiming to improve patient outcomes in cardiac and respiratory health.

What Products and Services Does BCDA Offer?

• Develop advanced cellular and cell-derived therapies for cardiac and respiratory ailments.
• Focus on the CardiAMP Cell Therapy System for heart failure and chronic myocardial ischemia.
• Advance an allogeneic cell therapy program targeting cardiac and pulmonary conditions.
• Conduct Phase I/II clinical trials for investigational treatments.
• Provide innovative delivery solutions, including the Helix biotherapeutic delivery system.
• Offer Morph deflectable guides and sheaths for enhanced treatment delivery.

How Does BCDA Make Money?

• Generate revenue through the development and commercialization of innovative therapies.
• Engage in partnerships and collaborations with healthcare providers and research institutions.
• Focus on securing funding through grants and investments to support R&D efforts.
• Monetize proprietary delivery technologies and systems in conjunction with therapies.

What Industry Does BCDA Operate In?

The biotechnology industry is rapidly evolving, with a strong emphasis on regenerative medicine and cell-based therapies. The global regenerative medicine market is projected to grow significantly, driven by advancements in cell therapy, gene therapy, and tissue engineering. BioCardia, Inc. is strategically positioned within this landscape, focusing on innovative treatments for cardiac and respiratory diseases. The competitive landscape includes several players in the regenerative medicine space, but BioCardia's unique approach with the CardiAMP Cell Therapy System and its proprietary delivery technologies differentiate it from others. As the demand for effective treatments for chronic conditions increases, BioCardia's focus on these therapeutic areas aligns well with market trends.

Who Are BCDA's Key Customers?

• Healthcare providers seeking advanced treatment options for cardiac and respiratory conditions.
• Patients suffering from heart failure and chronic myocardial ischemia.
• Research institutions interested in regenerative medicine and cell therapy advancements.
• Investors looking for opportunities in the biotechnology sector.

Company Profile

BioCardia, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Sunnyvale, US. The company is led by CEO Peter A. Altman. BCDA has traded publicly since 1996.

Key Financial Metrics

A current ratio of 0.41 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -58.0%, the inverse of the P/E and a quick read on earnings relative to price.

BCDA Valuation & Market Position

Relative to its peer group, BCDA's quantitative score of 29/100 is below the peer average of 86/100.

Quarterly Financial Performance: BioCardia, Inc.

Revenue for BioCardia, Inc. came in at $0 during Jun 2026. The company recorded a net loss of $1.6M, with diluted EPS of $-0.13. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, BCDA averaged $-0.19 in diluted EPS.

BioCardia, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

BioCardia, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 10.9% above estimates on average.

Wall Street analysts project BioCardia, Inc. revenue of about $50K for fiscal 2026, with EPS near $-0.63.

Over the past six months, BioCardia, Inc. insiders filed 40 SEC Form 4 transactions — 3 sales and 37 purchases. On net that is roughly 459K shares acquired (about $505K) — insiders putting money in tends to read as conviction.

BCDA Financials

BCDA Latest News

BCDA Analyst Consensus

BCDA MoonshotScore

BCDA Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources